We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





COVID-19 Severity Test Reads Immune System in Real Time Using Machine Learning for Predicting Severe Outcomes

By LabMedica International staff writers
Posted on 28 Jul 2021
Print article
Image: MeMed COVID-19 Severity (Photo courtesy of MeMed)
Image: MeMed COVID-19 Severity (Photo courtesy of MeMed)
A new COVID-19 test reads the immune-system in real time to accurately determine whether SARS-Cov-2 patients are likely to have a severe outcome.

MeMed (Haifa, Israel) has received the CE Mark in Europe for its new disease management solution, MeMed COVID-19 Severity - a pioneering host response technology that measures multiple proteins from a serum sample and applies machine learning to stratify the risk that a patient with COVID-19 disease is likely to experience severe outcomes. The test runs in 15 minutes on the company’s point-of-need platform, MeMed Key, and aims to help physicians identify who may benefit from escalated care and who may be safely discharged from the hospital and instructed to self-isolate at home.

MeMed COVID-19 Severity is a predictive and actionable patient management tool. The test enables physicians to detect early the likelihood of deterioration in patients affected by COVID-19 and provides a leap forward in COVID-19 patient management. MeMed has recently published the results from a multinational derivation study, demonstrating the signature’s ability to accurately predict severe COVID-19 respiratory failure. The company has completed an additional independent multinational validation study; the results will be revealed in coming months.

“I am delighted that we are now able to commercialize a pioneering solution to help identify COVID-19 patients at risk of severe outcomes, empowering physicians to manage what is increasingly likely to become an endemic situation,” said Eran Eden, MeMed’s co-founder and CEO. “MeMed COVID-19 Severity is also relevant for authorities contemplating preparedness for future pandemics. It is another exciting step in the company’s long-term vision of harnessing the power of the host-immune response in order to transform the way infections are detected and managed.”

“Highly sensitive and accurate diagnostic and prognostic tests are key tools for clinicians,” said Sergey Motov, MD, Professor of Emergency Medicine, Maimonides Medical Center. “As an ER doctor myself, I am fascinated by the potential for host immune response technologies to help predict patient outcomes. Tools like MeMed COVID-19 Severity are a win-win solution: doctors can assess the likelihood of patients suffering from severe complications, enabling tailored treatments or discharge if the risk of deteriorating is low.”

Related Links:
MeMed

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.